Goldman Sachs Downgrades Healthways Inc. (HWAY) to Sell
More News related to HWAY
- Healthways to Present at the Credit Suisse 18th Annual Healthcare Conference
- Stifel Nicolaus Downgrades Healthways (HWAY) to Hold
- Jefferies & Co Upgrades Healthways (HWAY) to Buy
- Morning Movers 10/23: AMZN, CPWR, EPAY, ALGN, HWAY, SCSS, ACO Higher; ELN, SNV, CBRX, RMTR, STSA, DVAX Lower
- Piper Jaffray Upgrades Healthways (HWAY) to Neutral; Strong Execution in Tough Environment
More News related to Downgrades
- Kinross Gold (KGC) Receives Authorization to Re-Commence Exploration on Project in Ecuador
- Sanofi-aventis (SNY) and Regeneron Pharmaceuticals (REGN) to Expand Global Collaboration
- Stryker (SYK) Announces Two Acquisitions
- Adobe (ADBE) Cutting 680 Full-Time Jobs to Align Costs with '10 Operating Plan
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
Goldman Sachs downgrades Healthways Inc. (Nasdaq: HWAY) from Neutral to Sell but raises their price target from $9 to $10, which still suggest 31% downside to the current market price.
The firm cites several challenges including in-sourcing risk from national health plan clients and pricing pressure due to the economy among other things.
Healthways, Inc. provides specialized Health and Care Support solutions.
Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php
Related Categories
DowngradesTrader Talk
Stocks Mentioned
-0.06Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
